BioCryst Pharmaceuticals Inc (BCRX)
4.16
-0.05
(-1.19%)
USD |
NASDAQ |
Apr 25, 16:00
4.165
0.00 (0.00%)
After-Hours: 20:00
BioCryst Pharmaceuticals Gross Profit Margin (Quarterly): 98.25% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 98.25% |
September 30, 2023 | 98.69% |
June 30, 2023 | 98.85% |
March 31, 2023 | 98.64% |
December 31, 2022 | 96.86% |
September 30, 2022 | 95.24% |
June 30, 2022 | 99.62% |
March 31, 2022 | 99.52% |
December 31, 2021 | 99.11% |
September 30, 2021 | 98.50% |
June 30, 2021 | 99.31% |
March 31, 2021 | 68.92% |
December 31, 2020 | 97.98% |
September 30, 2020 | 74.99% |
June 30, 2020 | |
March 31, 2020 | 98.57% |
December 31, 2019 | 93.53% |
September 30, 2019 | 98.99% |
June 30, 2019 | 98.20% |
March 31, 2019 | 74.76% |
December 31, 2018 | 97.44% |
September 30, 2018 | 98.76% |
June 30, 2018 | 98.06% |
March 31, 2018 | 96.48% |
December 31, 2017 | 96.68% |
Date | Value |
---|---|
September 30, 2017 | 85.65% |
June 30, 2017 | 99.29% |
March 31, 2017 | 96.88% |
December 31, 2016 | 72.70% |
September 30, 2016 | 98.16% |
June 30, 2016 | 99.44% |
March 31, 2016 | 98.40% |
December 31, 2015 | 99.39% |
September 30, 2015 | 87.70% |
June 30, 2015 | 98.29% |
March 31, 2015 | 98.90% |
December 31, 2014 | 99.19% |
September 30, 2014 | |
June 30, 2014 | 99.66% |
March 31, 2014 | 97.89% |
December 31, 2013 | 99.84% |
September 30, 2013 | |
June 30, 2013 | 99.51% |
March 31, 2013 | 97.83% |
December 31, 2012 | 99.56% |
September 30, 2012 | 98.02% |
June 30, 2012 | |
March 31, 2012 | |
December 31, 2011 | |
September 30, 2011 |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
68.92%
Minimum
Mar 2021
99.62%
Maximum
Jun 2022
95.21%
Average
98.53%
Median
Gross Profit Margin (Quarterly) Benchmarks
AIM ImmunoTech Inc | 81.54% |
Perspective Therapeutics Inc | -- |
Protalix BioTherapeutics Inc | 15.54% |
Electromed Inc | 77.03% |
Armata Pharmaceuticals Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
Return on Assets | -43.08% |
Return on Invested Capital | -54.83% |
Profit Margin (Quarterly) | -66.09% |
Operating Margin (Quarterly) | -45.68% |
Return on Net Operating Assets | -238.1% |